Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
McKesson
Merck
Medtronic
Baxter

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 8,642,327

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,642,327
Title:Vector for inhibition-based high-throughput screen strategy
Abstract: A method for screening cells with high level expression of a target protein is disclosed. The method includes introducing into a plurality of host cells a DNA construct that encodes both a target protein and an inhibitor to an endogenous selectable marker in the host cells, screening host cells harboring the DNA construct for the expression of the endogenous selectable marker, and isolating cells with reduced expression of the selectable marker. Also disclosed is a DNA construct configured to express both the target protein and the inhibitor inside the host cell.
Inventor(s): Liu; Wei-Kuang (Taipei, TW), Ding; Min-Pey (Taipei County, TW)
Assignee: Scinopharm Taiwan, Ltd. (Tainan County, TW)
Application Number:13/231,436
Patent Claims:1. An expression vector for high-throughput screening of cells harboring the expression vector, comprising: a first nucleotide sequence, wherein the first nucleotide sequence is a transgene encoding a therapeutic molecule; a second nucleotide sequence encoding an exogenous selection marker for a host cell; a third nucleotide sequence encoding an inhibitor to an endogenous selection marker in the host cell; and one or more regulatory elements that control the expression of the first, second and third nucleotide sequences in the host cell, wherein the first nucleotide sequence is linked to the second nucleotide sequence by an internal ribosome entry site (IRES).

2. The expression vector of claim 1, further comprising one or more anti-repressor elements.

3. The expression vector of claim 2, wherein the one or more anti-repressor elements includes a partial mouse anti-repressor element 40.

4. The expression vector of claim 1, wherein the inhibitor is an interfering RNA.

5. The expression vector of claim 4, wherein the interfering RNA is a miR-30-based shRNA.

6. The expression vector of claim 1, wherein the endogenous selection marker is a fluorescent protein.

7. The expression vector of claim 6, wherein the fluorescent protein is green fluorescent protein.

8. The expression vector of claim 1, wherein the exogenous selectable marker is dihydrofolate reductase.

9. The expression vector of claim 1, wherein the one or more regulatory elements include a CMV IE enhancer.

10. The expression vector of claim 1, wherein the therapeutic molecule is Herceptin.

Details for Patent 8,642,327

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 1998-09-25 ⤷  Sign up for a Free Trial 2029-06-11
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 2017-02-10 ⤷  Sign up for a Free Trial 2029-06-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Mallinckrodt
Medtronic
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.